Physician profile
Mark J Adame
NPI 1346245669
$4,587.56
in general payments reported to CMS, 2019-2025
39 companies · $923 in 2025
The $923 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $173 · 2021: $95.65 · 2022: $214 · 2023: $1,262 · 2024: $1,029 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.06 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $553.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $547.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $387.94 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $312.76 | 2019-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $295.90 | 2019-2025 | Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $210.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.27 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $152.90 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Mylan Specialty L.P. | $134.33 | 2022-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $88.36 | 2019-2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Boston Scientific Corporation | $85.54 | 2019-2023 | Watchman |
| Allergan, INC. | $76.09 | 2019-2020 | |
| Amgen INC. | $73.25 | 2024-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $60.02 | 2023-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $57.98 | 2023 | Quviviq |
| Verity Pharmaceuticals INC. | $55.32 | 2024-2025 | Tlando |
| Lundbeck LLC | $51.64 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $48.79 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.41 | 2022 | |
| Sanofi Pasteur INC. | $43.95 | 2021 | |
| Optinose US, INC. | $41.93 | 2020-2023 | |
| Dexcom, INC. | $40.55 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $39.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Arbor Pharmaceuticals, INC. | $37.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $33.57 | 2019-2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $26.11 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $24.24 | 2025 | Auvelity |
| Embecta Corp. | $22.59 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Daiichi Sankyo INC. | $21.71 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.44 | 2019 | |
| Medtronic, INC. | $19.29 | 2024 | Venaseal |
| Myriad Women'S Health, INC. | $17.67 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $16.94 | 2022 | |
| Seqirus USA INC | $16.93 | 2019 | |
| Bausch Health US, LLC | $14.31 | 2023 | Aplenzin |
| Viatris Specialty LLC | $13.90 | 2025 | Yupelri |
| Genentech USA, INC. | $11.23 | 2019 | |
| Organon LLC | $4.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Adame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.